See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
Prediction of transmission mitigation based on the antiviral effect of Ensitrelvir and simulation of its impact on epidemics
Prediction of transmission mitigation based on the antiviral effect of Ensitrelvir and simulation of its impact on epidemics
Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access programme in Spain: results of the PERSEUS study
Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access programme in Spain: results of the PERSEUS study
Real-world effectiveness and safety of cefiderocol in the treatment of patients with serious Gram-negative bacterial infections: results of the PROVE chart review study
Real-world effectiveness and safety of cefiderocol in the treatment of patients with serious Gram-negative bacterial infections: results of the PROVE chart review study
Real-world effectiveness and safety of long-term (>28 days) cefiderocol treatment in patients with Gram-negative bacterial infections in the PERSEUS study in Spain
Real-world effectiveness and safety of long-term (>28 days) cefiderocol treatment in patients with Gram-negative bacterial infections in the PERSEUS study in Spain
You Are Viewing Congress Locations
GSA 2025
APCCMI 2025
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
